Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

    ... Neoplasms (MPN) (excluding PV, ET and primary/secondary myelofibrosis).  The study will enroll approximately 50 patients at ... Leukemia (aCML), Chronic Myelomonocytic Leukemia (CMML), MPN/MDS overlap syndromes, accelerated phase myelofibrosis and MPN unclassifiable. ...

    Clinical Trial last updated 05/14/2018 - 2:02pm.

  2. What is Secondary MDS? Everything You Need to Know

    ... Treatment-related MDS, also known as secondary MDS , makes up a small fraction of cases of MDS. It is most ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  3. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry

    ... BACKGROUND: Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders characterized by ... 40% of patients. Transfusion-dependent patients develop secondary iron overload . The influence of serum ferritin (SF) ...

    Research Article last updated 10/06/2016 - 1:01pm.

  4. What is Secondary MDS? Everything You Need to Know

    ... Treatment-related MDS, also known as secondary MDS , makes up a small fraction of cases of MDS. It is ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  5. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po

    ... and intermediate-1-risk) myelodysplastic syndromes (MDS) with poor prognostic features including anemia and/or ... according to International Working Group 2006 criteria. Secondary endpoints include overall survival, hematologic response including ...

    Research Article last updated 06/23/2016 - 10:17am.

  6. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... of RBC transfusion independence (TI) ≥ 8 weeks. Secondary end points were RBC-TI ≥ 24 weeks, duration of RBC-TI, erythroid ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 07/18/2016 - 10:30am.

  7. 2018 Bone Marrow Failure Disease Scientific Symposium

    ... and Poster Session Friday, March 23 Biology of MDS and Secondary Acute Myeloid Leukemia Non-Transplant Treatments for MDS and ...

    Page last updated 02/15/2018 - 2:39pm.

  8. Risk of developing MDS and AML after radiation treatment for breast cancer

    ... to access the full report. Abstract # 6560 Secondary or t-MDS It is important to recognize that, while secondary MDS (t-MDS) ...

    Research Review last updated 05/02/2016 - 9:32am.

  9. Foundation Update - July 2016

    ... • Growth Factors in Aplastic Anemia, MDS, and PNH ; July 19, 2016, 1:00 PM EDT ... Very Severe Aplastic Anemia • PNH: Secondary Mutations and Thrombosis • Transitioning ...

    Article last updated 10/09/2017 - 2:53pm.

  10. Eltrombopag Added to IST Yields Encouraging Results

    ... of eltrombopag may impact the risk of clonal evolution to MDS. A small portion (10-20%) of patients with aplastic anemia can develop MDS ... data following transplant. How important are the stated secondary outcomes: overall survival, overall response, relapse, and clonal ...

    Interview last updated 05/24/2017 - 7:44am.